Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.880 -0.110 (-2.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
360 DigiTech, HUTCHMED And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Agenus (AGEN) Q3 2022 Earnings Call Transcript
AGEN earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
10 Best Medical Stocks Under $5
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the... 
Via Talk Markets
VBI Vaccines, Agenus Ink Partnership For Combination Brain Cancer Therapy
 
Via Benzinga
Why Agenus Stock Rose 18.4% on Thursday
The company's shares climbed with help from insider buying. 
Via The Motley Fool
Short Volatility Alert: Agenus Inc.
On Tuesday, shares of Agenus Inc. (NASDAQ: AGEN) experienced volatile short activity. After the activity, the stock price went down 0.00% to $2.66. The overall sentiment for AGEN has been Neutral. 
Via Benzinga
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
From Agenus Inc.
Via GlobeNewswire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From Agenus Inc.
Via GlobeNewswire
Recap: Agenus Q2 Earnings
  Agenus (NASDAQ:AGEN) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares increased by 12.7% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $1.2 million. 
Via Benzinga
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday. 
Via Benzinga
Tilray Brands, Canopy Growth, Cronos Group And Other Big Gainers From Thursday
U.S. stocks closed lower with the Dow Jones dropping more than 300 points on Thursday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
Via Benzinga
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
From Agenus Inc.
Via GlobeNewswire
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Agenus Inc.
Via GlobeNewswire
7 Penny Stocks That Actually Have a Buy Rating
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now. 
Via InvestorPlace
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
 
Via Benzinga
Agenus Begins Mid-Stage Global Studies On Colorectal And Skin Cancer Candidate
Agenus (NASDAQ: AGEN) has initiated Phase 2 ACTIVATE trials of botensilimab to advance globally in metastatic patients who have progressed on available therapies. This global Phase 2 program include... 
Via Benzinga
Agenus Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Agenus (NASDAQ:AGEN) posted sales of $20.93 million. Earnings were up 2.71%, but Agenus still reported an overall loss of $49.23 million. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Agenus Commences Initial-Stage Advanced Tumors Study
Agenus (NASDAQ: AGEN) has dosed the first patient in the Phase 1 clinical study of AGEN1571 in advanced solid tumors. AGEN1571is a novel anti-ILT2 antibody designed to modulate tumor-associated... 
Via Benzinga
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET 
From Agenus Inc.
Via GlobeNewswire
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday. 
Via Benzinga
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering. 
Via Benzinga
U.S. Stocks Turn Negative; 2U Shares Spike Higher
U.S. stocks pared gains midway through trading, with all the three major indices turning lower on Wednesday. 
Via Benzinga
Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its previously announced at-the-market offering. 
Via Benzinga
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
 
Via Benzinga
Agenus's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Agenus (NASDAQ:AGEN) posted sales of $25.94 million. Earnings were up 25.15%, but Agenus still reported an overall loss of $50.60 million. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.